Time-Dependent Bias of Tumor Growth Rate and Time to Tumor Regrowth.
作者信息
Mistry H B
机构信息
Manchester School of Pharmacy, Manchester, UK.
出版信息
CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):587. doi: 10.1002/psp4.12145. Epub 2016 Nov 10.
Abstract
摘要
相似文献
1
Time-Dependent Bias of Tumor Growth Rate and Time to Tumor Regrowth.
CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):587. doi: 10.1002/psp4.12145. Epub 2016 Nov 10.
2
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
Int J Oncol. 2017 Aug;51(2):425-434. doi: 10.3892/ijo.2017.4036. Epub 2017 Jun 8.
3
Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de.
4
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Neuro Oncol. 2016 Feb;18(2):173-83. doi: 10.1093/neuonc/nov288. Epub 2015 Nov 30.
5
Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas.
Brain Tumor Pathol. 2016 Apr;33(2):129-36. doi: 10.1007/s10014-016-0248-6. Epub 2016 Jan 29.
6
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
J Thorac Oncol. 2014 Jun;9(6):775-83. doi: 10.1097/JTO.0000000000000170.
7
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
Cancer Res. 2009 Oct 1;69(19):7524-8. doi: 10.1158/0008-5472.CAN-09-0381. Epub 2009 Sep 8.
8
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
Tumour Biol. 2017 Jun;39(6):1010428317705509. doi: 10.1177/1010428317705509.
9
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Dis Colon Rectum. 2011 Aug;54(8):1026-35. doi: 10.1097/DCR.0b013e31821c44af.
10
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
N Engl J Med. 2003 Jul 31;349(5):427-34. doi: 10.1056/NEJMoa021491.
引用本文的文献
1
Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma.
CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):540-550. doi: 10.1002/psp4.13294. Epub 2024 Dec 25.
2
On the relationship between tumour growth rate and survival in non-small cell lung cancer.
PeerJ. 2017 Nov 29;5:e4111. doi: 10.7717/peerj.4111. eCollection 2017.
3
Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.
CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):560-568. doi: 10.1002/psp4.12209. Epub 2017 Jul 13.
4
A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.
CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):373-382. doi: 10.1002/psp4.12193. Epub 2017 May 26.
5
Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry.
CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):225. doi: 10.1002/psp4.12163. Epub 2017 Apr 11.
本文引用的文献
1
Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.
CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):352-8. doi: 10.1002/psp4.12064. Epub 2016 Jul 12.
2
Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.
J Clin Oncol. 2013 Jun 10;31(17):2110-4. doi: 10.1200/JCO.2012.45.0973. Epub 2013 May 6.
3
Immortal time bias in pharmaco-epidemiology.
Am J Epidemiol. 2008 Feb 15;167(4):492-9. doi: 10.1093/aje/kwm324. Epub 2007 Dec 3.
4
Time-dependent bias was common in survival analyses published in leading clinical journals.
J Clin Epidemiol. 2004 Jul;57(7):672-82. doi: 10.1016/j.jclinepi.2003.12.008.
Zotero 插件